Translators deal with a lot of challenges. Apart from making sure that text is grammatically correct and uses appropriate tone, they must also decide when and how to translate certain cultural aspects and linguistic nuances. This includes translating metaphors and idioms.
There isn’t one specific quality that sets an LSP apart from their competitors as the ‘best’ choice, but that doesn’t mean you can’t make an informed decision. Here, we have listed a number of criteria that you might want to give consideration to when choosing an LSP for your technical translations.
The global market for Apps is as competitive as it has ever been. With more and more local Apps being produced each day, someone is probably working on a localized version of your App as you’ve read this! It’s important to make sure your App is properly localized and that you iron out these common mistakes from the beginning.
At CSOFT, we appreciate our 10,000 experts around the world for their dedication to breaking down cultural and linguistic barriers, and strengthening global connections. Thank you to all linguists around the world for your passion and efforts in filling in the missing gaps and bringing people closer together.
Marketing translations is a vital step across all industries. Due to the cultural differences that affect global markets, you need to take special care when presenting your branding messages. Unlike technical documents, marketing communications material is highly visible and often written in highly expressive language. If you want to reach a global audience, it is essential to make sure your marketing messages resonate cross-culturally. Transcreation makes this possible.
An in-country review (ICR), also referred to as an in-house review, is an essential step in life science translations. With translations for industries such as medical, pharmaceuticals, and biotechnologies, accuracy is of the utmost importance. Generally, in-country reviews will be undertaken by someone on the client’s side.
Several years ago, clinical trials in India were a booming business. After becoming fully compliant withTRIPS in 2005, India was seen as a favorable place to conduct clinical trials as they boast a huge genetically diverse population, as well as a multitude of skilled health professionals. Additionally, it is estimated that India based clinical trials offered a 35-60% cost reduction compared to western based trials.